SCHEMBL1735408

SCHEMBL1735408

CC(C)(C)C(NC(=O)c1ccc(-c2cnc(Nc3ccc(OCCN4CCC(C(N)=O)CC4)cc3)nc2)cc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.46
▸ JAK1 P23458 3/20 0.46
▸ HDAC1 Q13547 3/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ RET P07949 1/20 0.46
▸ TYK2 P29597 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ MCHR1 Q99705 1/20 0.46
▸ HRH3 Q9Y5N1 3/20 0.46
▸ LTA4H P09960 5/20 0.45
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ EGFR P00533 2/20 0.39
▸ HRH2 P25021 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734488 0.88 HRH3 (0.56) BRD4JAK1HDAC1JAK2RET
SCHEMBL4775821 0.84 MCHR1 (0.50) BRD4JAK1HDAC1JAK2RET
SCHEMBL1734148 0.84 BRD4 (0.47) BRD4JAK1HDAC1JAK2RET
SCHEMBL13605326 0.83 MCHR1 (0.55) BRD4JAK1HDAC1JAK2RET
SCHEMBL4794442 0.81 MCHR1 (0.53) BRD4JAK1HDAC1JAK2RET
SCHEMBL1735388 0.78 HRH3 (0.52) JAK2JAK3MCHR1HRH3
SCHEMBL1735235 0.77 LTA4H (0.52) BRD4JAK1HDAC1JAK2RET
SCHEMBL13605312 0.76 BRD4 (0.46) BRD4JAK1HDAC1JAK2RET
SCHEMBL13605345 0.75 BRD4 (0.47) BRD4JAK1HDAC1JAK2RET
SCHEMBL3644492 0.75 LTA4H (0.49) BRD4JAK1HDAC1JAK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928236-B1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC (BM) 2011-11-23 — — EP claimed
US-7592349-B2 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors IRM LLC (BM) 2009-09-22 — — US claimed
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2008-06-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE BRD4 1881/4885JAK1 737/4885HDAC1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback